Around 130 AstraZeneca staff will transfer to Sobi as the Swedish company, widely known as Sobi, takes over marketing of the drug Synagis in the United States.
AstraZeneca sells infant drug rights to Sobi for $1.5 bln upfront
More from Industry NewsMore posts in Industry News »
- FDA panel endorses booster shot for J&J Covid-19 vaccine
- Intas launches the World’s first SB-100mg Itraconazole
- Second J&J COVID-19 shot gets expert backing; FDA is looking at lowering age for Pfizer booster
- StayHappi pharmacy enters Assam with 70 stores
- Mumbai: Larger ITAT bench to rule on pharma freebies